 |
William Poole
President, CEO
William
Poole has over thirty years of
extensive experience in the
bio-pharmaceutical and medical
device industries . From 1972 to
early 1996, Mr. Poole worked for
Lederle Laboratories, a Division of
American Cyanamid Company. During
his 24-year career at Cyanamid, Mr.
Poole held positions of increasing
responsibility and held the position
of World-Wide Division President of
the Medical Device Division when
Wyeth acquired Cyanamid in 1995.
After a brief stint as President of
Fisons Pharmaceuticals, which was
acquired by Rhone Poulenc-Rorer,
Bill went on to become President,
North American Pharmaceuticals, of
Novo Nordisk Pharmaceuticals, where
he served from 1997 to 2000. From
2001 to 2003, he served as President
of Biovail Pharmaceuticals. In both
of these companies, Mr. Poole was
instrumental in aggressively growing
revenue, building a solid management
team and dramatically improving
profitability. As President of these
firms, Mr. Poole had total P&L
responsibility and directly managed
vice presidents in charge of
manufacturing, sales, research &
development, legal, marketing,
finance, regulatory and human
resources functions.
Since his departure from Biovail,
Bill
has acted as an independent
consultant to the pharmaceutical
industry.
Avinash Nangia, PhD
Senior Vice President,
Research & Development
Dr. Avinash Nangia has more than
15 years of drug delivery
experience, successfully taking
numerous drugs from development to
market, while holding research
management positions at Alza
Corporation, Glaxo Canada, Inc., and
Andrx Pharmaceuticals, Inc.
Prior to joining Spherics, Dr.
Nangia was Director of Research and
Development at Andrx, where he was
responsible for new technology
development and ANDA/NDA development
from preclinical development through
Phase IV product support. While at
Alza, Dr. Nangia served as Research
Fellow and Manager in Oral Product
Development Group. At Glaxo, he was
Group Leader for Pharmaceutical
Research and Senior Research
Scientist for Intramural Basic
Research.
Dr. Nangia holds a PhD in
Pharmaceutics at the University of
Otago, New Zealand and post-doctoral
fellowship at the University of
California, San Francisco. He
received his MS degree in
Pharmaceutics at the Institute of
Technology, BHU, India; and a BS
degree in Pharmacy at the University
of Delhi, India. Dr. Nangia holds
more than 35 issued/pending patents
in the areas of product development
and novel drug delivery systems. He
is author of more than 45 research
papers published in peer reviewed
scientific journals and book
chapters and is a member of the
American Association of
Pharmaceutical Scientists,
Controlled Release Society and the
American College of Clinical
Pharmacology.
Michael Gattoni, CPA
Vice President, Finance and
Administration
Michael Gattoni has over
fourteen years of experience in
accounting and finance. Prior to
joining Spherics in May 2005, Mr.
Gattoni served as the Acting
Director of Financial Planning and
Analysis at Tyco Healthcare (a $10
billion multi-national manufacturer
of medical devices). His other
experiences include Manager of
Internal Controls (Sarbanes-Oxley)
and Logistics Operations Finance
Manager at Tyco Healthcare,
Controller for Commonwealth Wine &
Spirits (a privately held wine
distributor), Financial Analyst for
Duro Industries (textiles
manufacturer) and four plus years of
public accounting for two regional
CPA firms.
Michael holds a bachelors degree
from Providence College and is a
Certified Public Accountant.
Mark Iampietro
Vice President, Quality &
Regulatory Affairs
Mark Iampietro has twenty nine
years of quality experience with
pharmaceuticals, biologics and
medical devices. He has experience
in both FDA and international
regulatory affairs (MCA, ISO 9000,CE
Marking) in quality, statistical
analysis, analytical methods, and
stability programming. He is a
member of the American Society for
Quality (ASQ) and is certified as
both a Quality and Reliability
Engineer through the society. Mr.
Iampietro served as the Director of
Quality at Cynosure, Inc.
(1998-2002) and MedChem Products, a
division of C.R. Bard, (1994 to
1998). From 1981 to 1994, he served
in management roles of increasing
responsibility at Summit Technology,
Inc., Tambrands, Inc., and DelMad,
Inc. In addition to his quality
systems responsibilities, Mr.
Iampietro has served as a key
contributor to the development of
regulatory strategies for clinical
studies and earliest approval
options.
Mark holds a BS in Life Science from
Worcester Polytechnic Institute with
post graduate studies in statistics
and experimental design at the
University of Massachusetts and the
University of Arizona.
 George
Grandolfi
Senior Director - Product
Development
Dr. George Grandolfi has over 18
years experience in the
pharmaceutical industry, most
notably in the area of CMC
development.
He is currently responsible
for all formulation development,
process development, and
manufacturing activities at
Spherics.
From 1998-2007,
Dr. Grandolfi was Director of Product
Development at Alkermes where he managed
the formulation, process and
analytical development efforts for
the Oral
Technologies and Medisorb®
Sustained Release Injectables
drug delivery platforms, later
assuming overall project leadership
responsibilities.
From 1992-1998, Dr. Grandolfi
held various positions at Cephalon,
most notably
Director, Formulation Development.
He was responsible for
formulation and process development,
clinical trial materials
manufacturing, clinical packaging
and labeling, and stability.
Dr. Grandolfi worked as
a Research Scientist in parenteral
dosage form development at the
DuPont Merck Pharmaceutical Company.
He began his career as a
Pharmaceutical Scientist in solid
oral dosage form development at
Boehringer Ingelheim
Pharmaceuticals.
He led and
contributed to the scientific and
technical product development of
three approved NDAs.
In addition to his industry
career, Dr. Grandolfi has also been
an instructor of undergraduate
pharmaceutics courses at the
Ohio
State
University.
Dr.
Grandolfi holds a B.S. in Pharmacy
from the University of Rhode Island,
a M.S. in Pharmaceutics from the
University of Wisconsin–Madison, and
a Ph.D. in Pharmaceutics and
Pharmaceutical Chemistry from the Ohio State University.
He is a member of the
American Association of
Pharmaceutical Scientists, the
Parenteral Drug Association, and the
Controlled Release Society.
BACK TO TOP
|
|
